Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

D. Ross Camidge, Liza C. Villaruz, Jeffrey W. Clark et al.|Journal of Clinical Oncology|2018

Cited by 80